LENZ Therapeutics, Inc. and Lunatus Marketing & Consulting FZCO ("Lunatus") announced an exclusive distribution agreement for Lunatus to register and commercialize VIZZTM for the treatment of presbyopia in the Middle East Region. LENZ Therapeutics is a pharmaceutical company focused on the commercialization of VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of pres byopia. Lunatus is an independent pharmaceutical company specialized in the commercialization of pharmaceutical products in the Middle East.
Under the terms of the agreement, LENZ will receive upfront, regulatory and commercial milestone payments, in addition to a significant share of revenue generated in the region through a pre-determined minimum product supply price. Lunatus will retain exclusive commercialization rights for VIZZ for the treatment of presbyopic in the Middle East region, including United Arab Emirates, Kingdom of Saudi Arabia, Kuwait, Qatar, Bahrain, Oman, Jordan, Lebanon and Iraq.
